Furthermore, our study suggests that inhibition of MDM2 could re-sensitize drug-resistant MM cells to current anti-myeloma drugs, providing the rationale for the use of MX69 in combination therapy. This evidence concerns the gene MDM2 and Miyoshi myopathy.